Skip to Content

Oncotelic Therapeutics Inc OTLC

Morningstar Rating
$0.04 0.00 (6.19%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OTLC is trading at a 63% discount.
Price
$0.04
Fair Value
$3.32
Uncertainty
Extreme
1-Star Price
$7.17
5-Star Price
$3.33
Economic Moat
Lvr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OTLC is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.04
Day Range
$0.040.04
52-Week Range
$0.010.05
Bid/Ask
$0.04 / $0.04
Market Cap
$15.75 Mil
Volume/Avg
35,004 / 96,497

Key Statistics

Price/Earnings (Normalized)
Price/Sales
232.20
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.74%

Company Profile

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under the pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
22

Valuation

Metric
OTLC
Price/Earnings (Normalized)
Price/Book Value
1.35
Price/Sales
232.20
Price/Cash Flow
Price/Earnings
OTLC

Financial Strength

Metric
OTLC
Quick Ratio
0.02
Current Ratio
0.02
Interest Coverage
−6.05
Quick Ratio
OTLC

Profitability

Metric
OTLC
Return on Assets (Normalized)
−4.73%
Return on Equity (Normalized)
−10.22%
Return on Invested Capital (Normalized)
−1.84%
Return on Assets
OTLC
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRhhpwwxhbNzpw$550.4 Bil
VRTX
Vertex Pharmaceuticals IncXrhddpvXqwdtqj$101.7 Bil
REGN
Regeneron Pharmaceuticals IncMnxcpfksXmylvhy$98.1 Bil
MRNA
Moderna IncLdbbtjcjJnv$38.8 Bil
ARGX
argenx SE ADRFpxkbjxjKtz$21.7 Bil
BNTX
BioNTech SE ADRCrrhrpvVfzw$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncJtvdmtfpLrpgxn$18.4 Bil
BMRN
Biomarin Pharmaceutical IncCdxghtjwtSqfnbtv$17.1 Bil
RPRX
Royalty Pharma PLC Class AMpvlfkbqJpsdsm$12.5 Bil
INCY
Incyte CorpPgxxshgbYpbdvb$11.9 Bil

Sponsor Center